Search results
Kluczowe wnioski. W uwzględnionych badaniach porównano stosowanie remdesiwiru wraz ze standardową opieką zdrowotną lub standardową opieką zdrowotną (z placebo lub bez niego) u hospitalizowanych chorych na COVID-19. Pacjenci hospitalizowani z umiarkowanym lub ciężkim przebiegiem COVID-19.
- English
With moderate-certainty evidence, remdesivir probably makes...
- Bahasa Malaysia
Kami mencari kajian yang menyiasat remdesivir untuk merawat...
- Deutsch
In keiner Studie wurden Personen mit symptomloser...
- Remdesivir
中度至重度 covid-19 的住院患者. 瑞德西韋可能對 28 天、60 天後的死亡或 150...
- English
22 gru 2021 · A 3-day course of remdesivir had an acceptable safety profile and prevented disease progression resulting in hospitalization among high-risk patients with Covid-19.
15 paź 2024 · Przeciwwirusowy lek remdesivir mogą otrzymać bezpłatnie pacjenci z ciężkim przebiegiem COVID-19 w przypadku stwierdzenia określonych jednostek chorobowych.
14 wrz 2021 · Here we report the results of the DisCoVeRy trial comparing remdesivir to control in hospitalised patients with COVID-19. Remdesivir administration was well tolerated but was neither associated with a better clinical outcome at day 15 and 29 nor with a faster viral clearance.
21 lut 2023 · This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
22 maj 2020 · We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract...
9 sie 2023 · Eligible patients received intravenous remdesivir at a dose of 200 mg on the first day and 100 mg on days 2 and 3. The efficacy endpoints were set as the need for COVID-19-related hospitalization and all-cause mortality in the following 28 days.
